Adverse reactions to beta 2-agonist bronchodilators.

K M Lulich, R G Goldie, G Ryan, J W Paterson
{"title":"Adverse reactions to beta 2-agonist bronchodilators.","authors":"K M Lulich,&nbsp;R G Goldie,&nbsp;G Ryan,&nbsp;J W Paterson","doi":"10.1007/BF03259844","DOIUrl":null,"url":null,"abstract":"<p><p>Beta 2-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by beta-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another beta 2-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by beta 2-agonists. Side effects from beta 2-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a beta 2-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of beta 2-agonists used for long term therapy do not cause clinically significant desensitisation of airway beta-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses. Intravenous beta 2-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are presented.</p>","PeriodicalId":77871,"journal":{"name":"Medical toxicology","volume":"1 4","pages":"286-99"},"PeriodicalIF":0.0000,"publicationDate":"1986-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259844","citationCount":"39","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03259844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 39

Abstract

Beta 2-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by beta-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another beta 2-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by beta 2-agonists. Side effects from beta 2-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a beta 2-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of beta 2-agonists used for long term therapy do not cause clinically significant desensitisation of airway beta-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses. Intravenous beta 2-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are presented.

- 2激动剂支气管扩张剂的不良反应。
β 2激动剂是安全有效的支气管扩张药物。它们的主要不良反应是骨骼肌震颤、心动过速和各种代谢作用是由β -肾上腺素能受体刺激介导的,并且是可逆的。骨骼肌震颤是最常见的剂量限制副作用。可以通过低剂量开始治疗来减少,如果持续存在,可以尝试另一种β 2激动剂。其他副作用,如心律失常和PaO2降低是一些易感哮喘患者的严重潜在问题。然而,它们并不常见或程度较轻,通常被β 2激动剂对哮喘的良好控制所抵消。β 2激动剂治疗的副作用可以通过使用吸入途径选择性地将药物输送到气道来最小化。此外,对其副作用产生选择性耐受性。β 2激动剂的剂量应根据治疗效果和对其副作用的耐受程度来评估。推荐剂量用于长期治疗的β 2激动剂不会引起气道β -肾上腺素受体的临床显着脱敏,尽管这可能成为定期接受非常高剂量的患者的相关问题。静脉注射β 2激动剂在治疗对雾化器治疗无反应的严重哮喘中占有一席之地。在这种严重气流阻塞危及生命的情况下,应强制监测心率、PaO2、血浆钾和心电图,并给予补充氧气,以免出现严重的不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书